Piper Sandler analyst Matt O’Brien lowered the firm’s price target on Sight Sciences (SGHT) to $3.50 from $5.50 and keeps a Neutral rating on the shares. The firm notes the company reported Q4 results with sales that came in at the high end of their preannounced range. Nonetheless, the impact from the LCDs is expected to weigh on the 2025 topline and the company guided below Street expectations. While Piper believes management has prudently incorporated many possible headwinds into guidance, it worries these LCDs are likely to slow down the entire MIGS market which will have an outsized impact on Sight Sciences.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SGHT:
- Sight Sciences Faces Headwinds in Glaucoma and Dry Eye Markets, Hold Rating Maintained
- Sight Sciences Reports 2024 Results and 2025 Outlook
- Sight Sciences sees FY25 revenue $70M-$75M, consensus $78.07M
- Sight Sciences Reports 2024 Financial Results and 2025 Outlook
- Sight Sciences reports Q4 EPS (23c), consensus (18c)